JAMP Temozolomide Capsules Recalled for Assay Defect: Health Canada

Health Canada has classified a recall of JAMP Temozolomide capsules as a Type II health hazard, ordering the affected lot pulled from retail pharmacies nationwide. The recall was dated August 26, 2026, and formally published on August 31, 2026, under identification number RA-82571, with the depth of recall listed as retailers.

The action was initiated by JAMP Pharma Corporation, the Boucherville, Quebec-based manufacturer of the product, after testing found that the active pharmaceutical ingredient did not meet its approved specification for potency.

What Products Are Being Recalled?

The recall covers a single lot of ‘JAMP Temozolomide’, an oral capsule sold under Market Authorization DIN 02516829. The affected capsules are the 140 mg strength, and the impacted lot number is RLTS0225A. No other strengths or lots of the product are included in this recall notice.

Temozolomide is a chemotherapy medication typically prescribed for certain types of brain tumours, and consistent, accurate dosing is critical to how the drug performs for patients relying on it as part of a treatment regimen.

Why Was This Recall Issued?

According to Health Canada, the issue stems from the active ingredient being ‘out of specification’ during assay testing. In plain terms, laboratory analysis of the affected lot found that the actual amount of temozolomide in the capsules fell outside the range approved for the product.

An assay failure like this means patients taking capsules from the affected lot cannot be certain they are receiving the intended dose of the medication. For a narrow-margin chemotherapy drug, that kind of variability is treated as a meaningful quality and safety concern, which is reflected in Health Canada’s Type II classification — a category reserved for situations where use of the product may cause temporary or medically reversible adverse health consequences.

Who Is Affected?

The recall applies to retailers and pharmacies across Canada that received lot RLTS0225A of JAMP Temozolomide. Health Canada’s notice lists the recall’s audience as the general public, healthcare professionals, and industry, indicating that both patients and the pharmacies or clinics that dispense the drug should take note.

Because temozolomide is dispensed through pharmacies rather than sold as an over-the-counter product, patients currently undergoing treatment are the group most directly affected and should check their prescription bottles against the lot number listed above.

What Should You Do?

• Check whether your JAMP Temozolomide capsules come from lot RLTS0225A, DIN 02516829, 140 mg strength.
• Do not stop taking the medication on your own — speak with your healthcare provider before discontinuing use or making any changes.
• Contact your healthcare provider promptly if you have any health concerns related to this product.
• Reach out to JAMP Pharma Corporation directly with any questions about the recall.
• Report any side effects to Health Canada through its MedEffect Canada adverse reaction reporting program.
• Report any other safety complaints about the product to Health Canada.

What the Company/Agency Said

Health Canada’s published notice states plainly that ‘the active ingredient (temozolomide) is out of specification in the affected lot,’ and directs anyone with the recalled product to consult their healthcare provider before discontinuing use or for any health concerns. The agency has categorized the case as a Type II recall and listed JAMP Pharma Corporation, located at 1310 rue Nobel in Boucherville, Quebec, as the responsible company.

No additional public statement from JAMP Pharma Corporation was included in the Health Canada listing. The recall notice remains published on the Recalls and Safety Alerts database, and Health Canada says it will continue to monitor the situation as more information becomes available.